369P - Being there for women with metastatic breast cancer. A pan-European patient survey

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Supportive Care
Breast Cancer, Metastatic
Presenter Christopher Twelves
Authors C. Twelves1, J. Stebbing2
  • 1Clinical Cancer Research Groups, Leeds Institute of Molecular Medicine and St James’s Institute of Oncology, Leeds/UK
  • 2Oncology, Imperial College & Imperial College Healthcare NHS Trust, W2 - 1NY/UK



This two-part European patient survey was designed to help identify needs of women with metastatic breast cancer (MBC), through understanding their experiences of diagnosis, treatment and care.

Material and methods

The survey, initiated in March 2011, was conducted using a two-stage methodology. The first stage collected views on standards of MBC care and unmet needs of patients from 47 MBC-related patient groups in 8 European countries. This information was used to develop the second stage patient survey. The patient survey was designed to capture personal experiences of MBC diagnosis, treatment, information provision and to determine insights into the ‘trade-off’ between extending overall survival and side effects associated with MBC treatment. This online survey was open to women with locally advanced or MBC or their carers. All data were collected using anonymised local language questionnaires with responders recruited through local patient groups.


A total of 230 responses were received from 17 identified European countries (94% of whom had locally advanced or MBC, and 6% of whom were adult carers). Although the overall experience of care was generally good to excellent (77%), there were still gaps in terms of treatment choice and information provision. Specifically, findings indicate that 32% of patients perceived treatment choice to be lacking. Overall, results showed that 67% of women with locally advanced or MBC believed life-extending treatment to be important so that they could spend more time with their family and friends; the same proportion judged their treatment worthwhile if it prolonged survival, irrespective of potential side effects. Additionally, 68% of responders would have liked more information about future medical treatments and research, with 57% wishing to receive this information from their oncologist.


These new survey findings highlight the unmet needs of women with MBC in Europe with respect to treatment choice and provision of information. Prolonging survival is a priority for most women, even if associated with toxicity.


C.J. Twelves: The Being There survey was supported by an educational grant from Eisai Europe Limited.

J. Stebbing: The Being There survey was supported by an educational grant from Eisai Europe Limited.